For Investors

Latest News

View All News

March 10, 2026 7:00 AM EDT

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

Mar 9, 2026 7:00 am EDT

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Feb 23, 2026 7:00 am EST

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Feb 12, 2026 8:30 am EST

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

View All News

Latest Presentation

Mar 9, 2026 Corporate Presentation, March 2026

View All Presentations

Latest Event

Mar 10, 2026 7:00 am EDT – 8:00 am EDT

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference

View All Events

Latest Financial Results

Q2 2026

Quarter Ended Dec 31, 2025

Earnings Release PDF

10-Q PDF XBRL Zip

View All Financial Results

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2025

View 10-K

Company Overview

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD).

View Management Team View Board of Directors

IR Contacts

Headquarters

Benitec Biopharma Inc.
3940 Trust Way
Hayward, CA 94545
T: +1 (510) 780-0634

Investor Relations

LifeSci Advisors
Irina Koffler
Managing Director
T: 646-970-4681
ikoffler@lifesciadvisors.com

Transfer Agent

Computershare Investor Services
P.O. Box 505005
Louisville, KY 40233-5005
T: 781-575-3100